Compare Sirius XM Holdings Inc (SIRI) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sirius XM Holdings Inc vs TransMedics Group Inc — how do they compare? Sirius XM Holdings Inc trades at $28.71 (market cap $9.71B), while TransMedics Group Inc trades at $85.89 (market cap $3.06B). The key difference: Sirius XM Holdings Inc is far larger — about 3.2× TransMedics Group Inc's market cap, and Sirius XM Holdings Inc pays a 3.75% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| SIRI | TMDX | |
|---|---|---|
Market Cap | $9.71B | $3.06B |
Sector | Media | Technology |
52-Week High | $32.59 | $150.42 |
52-Week Low | $19.92 | $61.99 |
Enterprise Value | $18.99B | $3.46B |
Dividend Yield | 3.75% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sirius XM Holdings (SIRI) trades at $28.80, down 0.66% today, with a bullish technical signal from moving averages and neutral oscillators. Recent earnings show mixed results, with Q1 2026 beating expectations but Q4 2025 and Q2 2026 missing. The company maintains solid profitability with a 10.23% net income margin and trades at a P/E of 11.57, below industry averages. Key developments include a YouTube partnership expected to boost EBITDA by $350–400 million by 2029, as reported by Seeking Alpha on September 8, 2026.
SIRI presents a value opportunity with undervalued metrics and analyst consensus pointing to 21% upside to the $34.86 price target. Risks include volatile earnings performance and high debt levels, though debt-to-asset ratios have improved from 94.31% in 2022 to 35.63% in 2025. Institutional interest is strong, with BlackRock and Deutsche Bank increasing stakes in Q2 2026 per SEC filings.
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.
The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sirius XM Holdings Inc
SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.
Read more on SIRI →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
